Personalised Medicine for Morbid Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01365416|
Recruitment Status : Recruiting
First Posted : June 3, 2011
Last Update Posted : May 6, 2019
The prevalence of morbid obesity (BMI > 40 kg/m2) is increasing rapidly in the UK, but the investigators lack a coherent strategy for detailed assessment and treatment of the individuals affected, who are at high risk of morbidity and early mortality. The investigators already know that more than 1 in 20 severely-obese individuals have a simple genetic cause of their obesity (usually inherited in an autosomal dominant pattern. Bariatric surgery is the most effective treatment for morbid obesity and certain surgeries can result in the remission of type 2 diabetes. However, some patient fail to achieve the weight loss or experience complications and re-operations. The investigators are unable to predict the outcomes of bariatric surgery particularly in relation to type 2 diabetes remission which is crucial for the assessment of risk to benefit balance before wider future applications of the surgery.
The investigators want to investigate the mechanism underlying Type 2 diabetes remission after bariatric surgery by A) examining the effect of Mendelian forms of obesity and diabetes on T2D remission, B) studying changes in expression profiling patterns in insulin-responsive tissues, C) identifying of eQTLs, and of other genetic variations affecting T2D remission and D) studying the role of epigenetic variation in T2D remission.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Genetic Analysis for Personalised Medicine for Morbid Obesity|
|Study Start Date :||November 2011|
|Estimated Primary Completion Date :||November 30, 2022|
|Estimated Study Completion Date :||November 30, 2022|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01365416
|Contact: Alexandra I Blakemore, Reader||020 7594 6511 ext email@example.com|
|Contact: Christina G Prechtl, PhD||020 33 13 0532 ext firstname.lastname@example.org|
|Imperial Weight Centre||Recruiting|
|London, United Kingdom|
|Contact: Christina Prechtl, PhD 02083835970 email@example.com|
|Sub-Investigator: Christina Prechtl, PhD|
|Principal Investigator:||Alexandra I Blakemore, Prof||Imperial College London|